STRATA Skin Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024

2 years ago

HORSHAM, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical…

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

2 years ago

Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of…

Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting

2 years ago

SYDNEY, Australia, March 13, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing…

IMUNON Files IND Application to Begin Human Testing of IMNN-101

2 years ago

Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided…

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

2 years ago

International Society for Cell & Gene Therapy (ISCT) Names Dr. Lowdell with the Career Achievement Award in Cell and Gene Therapy…

MIMEDX Introduces E-Commerce and Account Management Platform

2 years ago

Designed to Streamline Ordering, Payment Processing, and Reimbursement SubmissionsMARIETTA, Ga., March 13, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq:…

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

2 years ago

New pharmacokinetic data demonstrate Virtue® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without…

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

2 years ago

Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2…

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

2 years ago

PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE…

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

2 years ago

AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in…